Bosutinib

Indications and Usage

Bosutinib is FDA approved for the treatment of

• Adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.
• Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.

Side effects needing medical attention

Most common adverse reactions in adult and pediatric patients with CML are diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, hepatic dysfunction, headache, fever, decreased appetite respiratory tract infection, and constipation. 

The most common laboratory abnormalities in adult and pediatric patients are creatinine increased, hemoglobin decreased, lymphocyte count decreased, platelets decreased, ALT increased, calcium decreased, white blood cell count decreased, AST increased, absolute neutrophil count decreased, glucose increased, phosphorus decreased, urate increased, alkaline phosphatase increased, lipase increased, creatine kinase increased, and amylase increased.